Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: LDL receptor-transferrin fusion protein - Takeda

Drug Profile

Research programme: LDL receptor-transferrin fusion protein - Takeda

Alternative Names: LDL receptor-transferrin fusion protein research programme - Transkaryotic Therapies; LDL receptor-transferrin fusion protein research programme: Takeda; LDL-cholesterol lowering therapies research programme - Transkaryotic Therapies; LDLR/TF; Research programme: LDL-cholesterol lowering therapies - Takeda; TX-1501

Latest Information Update: 16 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipoproteinaemia type II

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 16 Feb 2005 Preclinical trials in Familial hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top